---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036996"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2026-08-11T12:40:21+00:00"
generated_at: "2026-08-11T12:45:14.448802+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech CEO op-ed touts Ampligen as biodefense antiviral; cites 100% Ebola survival in mouse model

## Summary
- CEO Thomas K. Equels published op-ed in Breaking Defense on Aug 11, 2026 promoting Ampligen (rintatolimod) as broad-spectrum antiviral.
- USAMRIID preclinical study cited: 100% survival in rintatolimod-treated Ebola mouse cohort vs 100% mortality in controls (Antiviral Research).
- Company seeking government support for further Ebola/Bundibugyo and coronavirus mechanism studies; cites Utah State SARS research.
- Disclosure: Ampligen not FDA-approved for Ebola, Bundibugyo, coronaviruses or any biodefense indication.
- Op-ed references ~1,200 COVID infections aboard USS Theodore Roosevelt to argue for biodefense preparedness.

## SEC filing metadata
- accession: 0001493152-26-036996
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2026-08-11T12:40:21+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315226036996/0001493152-26-036996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315226036996/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036996
- JSON: https://secwatch.observer/filing/0001493152-26-036996.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036996.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.